Hugo Vanderstichele
Overview
Explore the profile of Hugo Vanderstichele including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
5012
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cline E, Antwi-Berko D, Sundell K, Johnson E, Hyland M, Zhang H, et al.
J Prev Alzheimers Dis
. 2025 Feb;
:100082.
PMID: 39955261
Objective: Sabirnetug (ACU193) is a humanized monoclonal antibody selective for soluble amyloid beta oligomers (AβOs), synaptotoxins that are early and persistent triggers of Alzheimer's disease (AD). Sabirnetug pharmacodynamics were examined...
2.
Shaw L, Korecka M, Lee E, Cousins K, Vanderstichele H, Schindler S, et al.
Alzheimers Dement
. 2024 Nov;
21(1):e14264.
PMID: 39614747
Background: We describe the Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core major activities from October 2004 to March 2024, including biobanking ADNI cerebrospinal fluid (CSF), plasma, and serum biofluid samples,...
3.
Schindler S, Galasko D, Pereira A, Rabinovici G, Salloway S, Suarez-Calvet M, et al.
Nat Rev Neurol
. 2024 Jun;
20(7):426-439.
PMID: 38866966
Anti-amyloid treatments for early symptomatic Alzheimer disease have recently become clinically available in some countries, which has greatly increased the need for biomarker confirmation of amyloid pathology. Blood biomarker (BBM)...
4.
Yuan J, Pedrini S, Thota R, Doecke J, Chatterjee P, Sohrabi H, et al.
NPJ Aging
. 2023 Sep;
9(1):17.
PMID: 37666862
Osteoporosis and Alzheimer's disease (AD) mainly affect older individuals, and the possibility of an underlying link contributing to their shared epidemiological features has rarely been investigated. In the current study,...
5.
Shaw L, Vanderstichele H, Knapik-Czajka M, Blennow K, Trojanowski J
Clin Chem
. 2022 Sep;
68(10):1336-1337.
PMID: 36103266
No abstract available.
6.
Aveneau C, Hourregue C, Cognat E, Dumurgier J, Vanderstichele H, Vanmechelen E, et al.
Clin Chem Lab Med
. 2021 Sep;
60(1):e13-e17.
PMID: 34525273
No abstract available.
7.
Thijssen E, Verberk I, Vanbrabant J, Koelewijn A, Heijst H, Scheltens P, et al.
Sci Rep
. 2021 May;
11(1):9736.
PMID: 33958661
Plasma biomarkers that reflect specific amyloid beta (Abeta) proteoforms provide an insight in the treatment effects of Alzheimer's disease (AD) therapies. Our aim was to develop and validate ready-to-use Simoa...
8.
Paciotti S, Stoops E, Francois C, Bellomo G, Eusebi P, Vanderstichele H, et al.
Clin Chem Lab Med
. 2021 May;
59(10):1653-1661.
PMID: 33957709
Objectives: Cerebrospinal fluid α-synuclein (CSF α-syn) represents a possible biomarker in Parkinson's disease (PD) diagnosis. CSF blood contamination can introduce a bias in α-syn measurement. To date, CSF samples with...
9.
Chatterjee P, Tegg M, Pedrini S, Fagan A, Xiong C, Singh A, et al.
Int J Mol Sci
. 2021 Apr;
22(6).
PMID: 33805778
Plasma amyloid-beta (Aβ) has long been investigated as a blood biomarker candidate for Cerebral Amyloid Angiopathy (CAA), however previous findings have been inconsistent which could be attributed to the use...
10.
Hansson O, Batrla R, Brix B, Carrillo M, Corradini V, Edelmayer R, et al.
Alzheimers Dement
. 2021 Mar;
17(9):1575-1582.
PMID: 33788410
The core cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers amyloid beta (Aβ42 and Aβ40), total tau, and phosphorylated tau, have been extensively clinically validated, with very high diagnostic performance for...